Acetyl octapeptide-3
SNAP-8, Ac-EEMQRRAD-NH2, acetyl octapeptide-1 (occasional variant naming)
Acetyl octapeptide-3 is acetyl hexapeptide-8 with two extra residues (alanine and aspartate) added to the C-terminus, extending its overlap with the SNAP-25 N-terminal region. It is marketed as a more potent successor to the hexapeptide. That claim rests almost entirely on supplier technical literature: a search of the peer-reviewed record turns up no dedicated, independent, controlled human efficacy trial of this peptide on its own.
Mechanism
The design logic is a direct extension of acetyl hexapeptide-8. SNAP-25 contributes two helices to the SNARE four-helix bundle that drives calcium-dependent vesicle fusion and acetylcholine release at the neuromuscular junction. Acetyl hexapeptide-8 reproduces the first six residues of SNAP-25. Acetyl octapeptide-3 adds alanine and aspartate to reproduce eight, on the reasoning that a longer mimic makes more contacts with the assembling complex and competes more effectively. Both peptides are N-acetylated and C-terminally amidated to blunt exopeptidase attack.
Every structural argument that applies to the hexapeptide applies here with greater force. The octapeptide is larger, carries additional negative charge from the added aspartate, and is therefore, if anything, less likely to traverse the stratum corneum passively. The hexapeptide's measured penetration into human epidermis was 0.01% of an applied dose in an FDA diffusion-cell study; nothing suggests the octapeptide does better. There is no published measurement of acetyl octapeptide-3 penetration through human skin, no demonstration that it reaches a neuromuscular junction, and no in vivo evidence in any species that it inhibits muscle contraction. The mechanism as marketed is an extrapolation from a related peptide's in vitro behaviour, not an observation about this peptide in skin.
What the research shows
This is a case where the absence of evidence is the finding. A PubMed search for acetyl octapeptide-3 or SNAP-8 as a cosmetic peptide returns no dedicated randomised controlled trial, no independent efficacy study, and no skin-penetration study specific to this molecule. The widely quoted figures (a 63% reduction in wrinkle depth, superiority over the hexapeptide) originate from the developer's technical dossier and have not appeared in the peer-reviewed literature in a form anyone can scrutinise.
The closest thing to indexed human data is Avcil and colleagues (2020), a 12-week monocentric study of hyaluronic acid microneedle patches loaded with bioactive peptides. Acetyl octapeptide-3 was one ingredient among several. The formulation also contained arginine/lysine polypeptide, palmitoyl tripeptide-5, adenosine and seaweed extracts. There was no placebo or comparator arm. The patches were associated with a 25.8% decrease in fine lines and wrinkles, 15.4% improvement in hydration, and 14.2% and 12.9% increases in dermal density and thickness. The authors explicitly describe the composition as working in a multi-targeted manner with ingredients possibly acting synergistically, and make no attempt to attribute the result to any single component. The author affiliations are commercial (Imperial Bioscience, Dermatest, Raphas). It is not evidence about acetyl octapeptide-3. It is an uncontrolled observation about a patch.
What can honestly be said: the design rationale inherits whatever credibility the acetyl hexapeptide-8 mechanistic work (Blanes-Mira 2002) has earned, and that work was done on a different molecule. The 2025 review of the hexapeptide concluded that even for the better-studied peptide, delivery is limited and the ability to reach neuromuscular junctions remains uncertain. For acetyl octapeptide-3 the position is weaker still, a plausible molecule with a coherent story and, so far as the public record shows, no controlled human trial of its own.
Evidence assessment
Preclinical only
No independent, peer-reviewed, controlled human trial of acetyl octapeptide-3 as a single agent could be located; the only indexed human data comes from an uncontrolled multi-ingredient microneedle patch study in which its individual contribution cannot be separated from four other actives.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
A synthetic hexapeptide (Argireline) with antiwrinkle activity Mixed evidence
Established that an N-terminal SNAP-25 mimetic hexapeptide interferes with SNARE complex formation and inhibits calcium-dependent exocytosis, with wrinkle depth reduced by up to 30% over 30 days.
Efficacy of bioactive peptides loaded on hyaluronic acid microneedle patches: A monocentric clinical study Limited evidence
Fine lines and wrinkles decreased 25.8%, hydration improved 15.4%, and dermal density and thickness increased 14.2% and 12.9%; the authors attribute the result to the multi-targeted composition as a whole and do not isolate any individual ingredient's contribution.
In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation Preclinical only
0.22% of the applied hexapeptide dose was recovered from human stratum corneum and 0.01% from the epidermis; none was detected in the dermis or the buffer beneath the skin.
Acetyl Hexapeptide-8 in Cosmeceuticals-A Review of Skin Permeability and Efficacy Mixed evidence
Concludes that limited stratum corneum permeability makes effective dermal delivery challenging and that the ability of this peptide class to reach neuromuscular junctions remains uncertain, with the underlying biological mechanisms incompletely understood.
Safety
No serious adverse effects have been reported, but this reflects the near-total absence of published human study rather than an established safety record. The peptide has been in cosmetic use for roughly two decades at typical formulation concentrations in the low single-digit percentages of a supplier solution (which is itself dilute), and no signal has emerged from post-market cosmetovigilance. What does not exist: dedicated repeat-insult patch testing in the peer-reviewed literature, long-term use data, any toxicology supporting a non-topical route, and any characterisation of what happens to the peptide once it enters the epidermis. Products sold as injectable acetyl octapeptide-3 under 'research use only' labelling have no safety basis at all. That phrase is a legal device permitting the sale of unapproved compounds to consumers, and carries no implication about purity, sterility or toxicology.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | Permitted as a cosmetic ingredient under the UK Cosmetics Regulation (retained EC No 1223/2009); it carries no Annex restriction or concentration limit. Efficacy claims must be substantiated under the Cosmetic Products Enforcement Regulations 2013. No MHRA marketing authorisation exists. |
| United States | A cosmetic ingredient requiring no FDA pre-market approval and holding none. It is not an approved drug for any indication. Marketing it with muscle-relaxant or botulinum-toxin-comparable claims would render the product an unapproved new drug. |
| WADA (sport) | Not listed on the WADA Prohibited List and not a monitored substance. |
Questions
That claim comes from supplier technical literature, not from a published head-to-head trial. No independent peer-reviewed study has compared the two in human skin. The structural argument (two more residues means more contact with the SNARE complex) is reasonable in a test tube, but it also makes the molecule larger and more negatively charged, which works against skin penetration.
None as a single agent that we could locate in the peer-reviewed record. The only indexed human study including it is a 2020 microneedle patch study where it was one of five actives, there was no control arm, and the authors explicitly declined to attribute the result to any one ingredient.
The developer's own technical dossier. It has not appeared in a peer-reviewed journal in a form that allows anyone to check the sample size, the control, the measurement method or the statistics. Treat it as a marketing claim until the underlying study is published.
There is no basis to say so. Every scrap of use experience with this peptide is topical and cosmetic. No toxicology, no pharmacokinetics, no human data exist for injection. Material sold in vials labelled 'for research use only' is not tested, approved or intended for human administration. That phrase exists to permit the sale of unapproved compounds, not to indicate they are safe.